Paclitaxel blocks Th2-mediated TGF-β activation in *Schistosoma mansoni*-induced pulmonary hypertension

Biruk Kassa, Claudia Mickael, Rahul Kumar, Linda Sanders, Dan Koyanagi, Daniel Hernandez-Saavedra, Rubin M. Tuder and Brian B. Graham

Program in Translational Lung Research, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

Abstract

Schistosomiasis is a leading cause of pulmonary hypertension (PH) worldwide. Recent studies reveal that the type-2 immune cytokines IL-4 and IL-13, as well as consequent activation of TGF-β, are key factors in the pathogenesis of *Schistosoma*-PH. Paclitaxel has been reported to act as an adjuvant for Th2 inflammation while downregulating TGF-β activation. Moreover, paclitaxel blocks PH in monocrotaline and SU5416-hypoxia models. We hypothesized that paclitaxel would augment Th2 inflammation while blocking TGF-β activation and PH after schistosomiasis exposure. Wild-type mice (C57BL6/J; 6/group) were intraperitoneally (IP) sensitized and then intravenously (IV) challenged with *Schistosoma mansoni* eggs. One day after IV egg challenge, the mice were treated with a single IP dose of 25 mg/kg paclitaxel or vehicle. Right ventricular (RV) catheterization was performed and granuloma volumes and vascular remodeling were quantified. Lung cytokines were quantified by ELISA and reverse transcription polymerase chain reaction, and the quantity of active TGF-β was determined using a cell reporter line. We also investigated hypoxia-induced PH. Paclitaxel treatment significantly protected mice from *Schistosoma*-PH, with decreased RV systolic pressure ($P = 0.005$) and pulmonary vascular media thickness. Inflammation was significantly suppressed, contrary to our hypothesis, with decreased IL-4 and IL-13 levels, smaller granulomas, and less active TGF-β following paclitaxel treatment. There was no change in IFN-γ or FoxO1 or FoxO3 expression. Paclitaxel did not suppress chronic hypoxia-induced PH, which is also TGF-β-driven but independent of type-2 immunity. Paclitaxel protects against *Schistosoma*-induced PH in mice, although by blocking proximate Th2 inflammation rather than suppressing distal TGF-β activation.

Keywords
parasitic infections, pulmonary hypertension experimental, inflammation

Date received: 26 July 2018; accepted: 30 November 2018

Pulmonary Circulation 2018; 9(1) 1–8
DOI: 10.1177/2045894018820813

Introduction

Schistosomiasis is a disease caused by infection of a snail-born parasite from the *Schistosoma* genus of trematodes. The common species that cause schistosomiasis are *Schistosoma mansoni*, *japonicum*, and *haematobium*. *Schistosoma* is highly endemic in sub-Saharan African nations as well as Brazil, the Middle East, and Southeast Asia. Over 200 million people are chronically affected with schistosomiasis, of which close to 6% develop World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) after chronic and recurrent *Schistosoma* infection. PAH is thought to predominantly occur in those infected with the species *S. mansoni* compared to the other endemic species. Despite the serious impact of schistosomiasis worldwide, it remains massively undertreated relative to the impact of the disease worldwide and thus is considered as one of the six “neglected tropical diseases.”

Recent findings indicate that the pathophysiology of experimental *Schistosoma*-pulmonary hypertension (PH),
and likely human *Schistosoma*-PAH, is significantly related to the inflammatory responses arising from host immune system. The primary response to the early larval antigens is type-1 immunity, which is characterized by the secretion of IL-1, IL-12, and INF-γ, cytokines also characteristic of Th1-polarized CD4 T cells. Adult worms do not trigger a substantial immune response themselves. However, once the worms start laying eggs in chronic infection, the immune response against the new released egg antigens is dominated by type-2 immunity, which is characterized by the production of cytokines IL-4, IL-5, IL-10, and IL-13: cytokines also characteristic of Th2-polarized CD4 T cells. Furthermore, the downstream effect of type-2 cytokines triggers the activation of transforming growth factor β (TGF-β), which is a key driver of smooth muscle and endothelial cell proliferation and vascular remodeling, which results in the PH phenotype. TGF-β is also associated with a Th17 immune response. We recently reported that in *Schistosoma*-induced PH, the protein thrombospondin-1 activates TGF-β, and that blocking thrombospondin-1 was protective against the PH phenotype. Thus, a therapeutic approach that specifically blocks TGF-β activation could be a novel approach to prevent or reverse *Schistosoma*-induced PH. It would be ideal to have this TGF-β inhibiting effect independent of the Th2 response, which could occur by modulating a Th1 or Th17 immune phenotype or directly inhibiting TGF-β, as blocking type-2 immunity in individuals who live in areas endemic for schistosomiasis could leave the host potentially susceptible to recurrent or poorly controlled infection.

One potentially attractive medication is paclitaxel, an FDA-approved drug that is a widely used chemotherapeutic. It inhibits cell division by binding to tubulin, which prevents the disassembly of microtubules. Paclitaxel is commonly used in breast cancer, ovarian cancer, lung cancer, and AIDS-related Kaposi sarcoma. A recent study suggested that paclitaxel can augment both type-1 and type-2 immunity in a model of ovalbumin sensitization and challenge. Paclitaxel treatment has also been shown to suppress TGF-β signaling in skin grafts in a scleroderma model and in hepatic stellate cells. Moreover, paclitaxel has recently been shown to augment the FoxO1 transcription factor, which blocks pulmonary vascular smooth muscle cell proliferation in monocrotaline and SU5416-hypoxia-exposed rats with experimental PH. Therefore, based on these data, we hypothesized that paclitaxel would augment type-2 immunity while blocking TGF-β activation and PH following *S. mansoni* exposure.

**Methods**

**Animal models**

Six-week-old C57BL6/J background wild-type (WT) mice were purchased from Jackson Laboratories. All animal studies and protocols were approved by the University of Colorado Institutional Animal Care and Use Committee.

**S. mansoni-induced PH**

We used our well-established mouse model of *S. mansoni*-induced PH, as described previously. Briefly, we harvested eggs from cercaria-infected Swiss Webster mice provided by NIAID Schistosomiasis Resource Center at the Biomedical Research Institute (Rockville, MD, USA). The experimental mice were intraperitoneally sensitized with 240 *S. mansoni* eggs per gram of mice weight and then intravenously challenged with 175 *S. mansoni* eggs per gram of mice two weeks later (experiment outline in Fig. 1a).

**Right ventricular systolic pressure (RVSP) and right ventricular hypertrophy measurement**

To measure RVSP, the mice were anesthetized with IP ketamine-xylazine and a tracheostomy placed for mechanical ventilation. The abdomen and diaphragm were surgically opened, and a 1-Fr pressure–volume catheter (PVR-1035, Millar AD Instruments, Houston, TX, USA) was placed directly into the right ventricle (RV) and then the left ventricle (LV) chambers through the free walls. The lungs were then flushed with phosphate buffered solution (PBS), the right lobes were sutured, and the left lung was inflated with 1% low melt agarose for formalin fixation and paraffin embedding (FFPE) for histology assessment. We divided the right lung lobes for protein by snap freezing quantification or placed in RNAlater (Life Technologies, Carlsbad, CA, USA) for RNA quantification. RV hypertrophy (Fulton Index) was measured by dividing RV mass by LV plus septum mass.

**Hypoxia-induced model of PH**

As described previously, WT mice were placed into hypoxia chamber with maintained 10% FiO2 at Denver altitude for two weeks. The partial pressure of oxygen was regulated by a flow of nitrogen gas into hypoxia chamber under the control of ProOx 110 (Biospherix) oxygen sensor.

**Paclitaxel treatment**

Paclitaxel (LC Laboratories, Woburn, MA, USA) was reconstituted in PBS and a dose of 25 mg/kg of mice was IP administered one day after intravenous augmentation of the mice (challenge) with *S. mansoni* eggs. The dose was selected as per the prior report. Control mice were given PBS only. In the chronic hypoxia model, paclitaxel was IP administered at a dose of 25 mg/kg of mice, at days 1 and 8.

**Vascular remodeling assessment**

Formalin-fixed and paraffin-embedded lung tissue was immunostained for α-smooth muscle actin (antibody from Dako, Agilent, Santa Clara, CA, USA) as previously reported. Images from stained slides were captured using Nikon Eclipse E800 microscope (Nikon, Melville, NY, USA) and CCD camera (Photometrics, Tucson, AZ,
The vascular media thickness was quantified using image processing software (Image Pro Plus v4.5.1, Media Cybernetics, Bethesda, MD, USA). The estimated granuloma volume assessment

The optical rotator stereological method was used to estimate the peri-egg granuloma volume. Images of hematoxylin and eosin (H&E)-stained granulomas that surround a single egg were captured. Peri-egg granuloma volumes were measured using image processing software (Image Pro Plus v4.5.1, Media Cybernetics, Bethesda, MD, USA) by using the egg as the center point.

Protein assessment and ELISA

Snap-frozen whole-lung tissue was macerated and sonicated in RIPA buffer containing anti-proteases. Bradford assay (5000201, BioRad, Hercules, CA, USA) was used to measure protein concentration. IL-4, IL-13, and IFN-γ protein concentrations in mouse lung lysates were quantified by ELISA using kits (M4000B, M1300CB, and MIF00, respectively) from R&D Systems (Minneapolis, MN, USA).

Messenger (mRNA) assessment

Whole-lung tissue banked in RNAlater was used to obtain RNA using Qiagen RNAeasy kit (Hilden, Germany). Reverse transcription polymerase chain reaction (RT-PCR) for IL-23, FoxO1, FoxO3, and β-actin was performed using commercially available primers (Mm00518984_m1 Il23a, Mm00490671_m1 Foxo1, Mm011185722_m1 Foxo3, and Mm02619580_g1 Actb, respectively) from Applied Biosystems (Foster City, CA, USA). The 2⁻ΔΔCt method was used for analyzing the results.

TGF-β assay and GRP-Rho A quantification

The concentrations of active TGF-β and GTP-RhoA in the whole lung was assessed as described previously. Briefly, whole-lung tissue lysates were added to a cellular assay using mink lung epithelial cells (MLEC) transfected with a human plasminogen activator inducer (PAI)-1 promoter having firefly luciferase reporter gene to detect TGF-β activity (MLECs were kindly provided by Dr. Daniel Rifkin, NYU). To measure total TGF-β concentration, lysates were heated for 20 min at 100°C. The luciferase activity was recorded as relative light units (RLU). RLU values were converted to TGF-β activity (pg/mL) using a standard curve generated using serial dilution of recombinant TGF-β1. To determine the concentration of active GTP Rho A, GLISA was performed using freshly made lung lysates. The activity was recorded at optical density (OD) of 490 nm using the GTP-RhoA GELISA kit (Cytoskeleton Inc. Cat. no. BK124).

Flow cytometry assessment

Lungs from the experimental mice were digested for flow cytometry assessment to identify IL-4 and IL-13 producing Th2 CD4⁺ T cells as described previously. In summary, experimental mice lungs were perfused with PBS, macerated and suspended in 1 mL of 0.4 mg/mL of liberase in RPMI, and put in a 37°C incubator for 30 min. The digested lungs were resuspended in plain 1 mL RPMI plus 100 μM EDTA and passed through an 18-gauge needle and then through a 16-gauge needle five times. The suspension was then filtered with a 100-μm filter and centrifuged at 1200 rpm for 10 min. The dispersed cells were resuspended in flow wash buffer (Invitrogen). Before staining extracellularly, cells were blocked for 20 min in ice using anti-CD16/CD32 antibody (1/50 dilution). The cells were incubated at 4°C for 30 min at 4°C with mouse AF700 anti-CD3 and mouse BV510 anti-CD4 antibodies, followed by fixation with IC fixation buffer for 20 min. Intracellular antibodies (mouse anti-INF-γ, anti-IL-4, anti-IL-17A, and anti-IL-17F labeled with PerCP-Cy5.5, AF488, APC, and PE, respectively) were diluted in permeabilization buffer (eBioscience, ThermoFisher Scientific) and incubated for 30 min at 4°C. The cells were then washed and ready for analysis. Acquisition was performed with a BD celesta flow cytometer.

Statistical analysis

SigmaPlot (version 13, Systat Software, San Jose, CA, USA) and ProStat (version 6, Poly Software International, Pearl River, NY, USA) were used to perform statistical analyses.
and presenting graphs. Statistical differences between the two groups were assessed by t-test. ANOVA was used to assess differences for ≥ 3 groups followed by post-hoc Tukey test. Non-normally distributed data was analyzed by non-parametric analysis. P values < 0.05 were considered statistically significant.

Results

Paclitaxel treatment protects from Schistosoma-induced PH

As shown in Fig. 1a, we sensitized female C57Bl/6 mice with S. mansoni eggs intraperitoneally, followed by intravenous challenge two weeks later. Previous utilization of this model demonstrates that the mice develop PH one week after challenge. One day after intravenous challenge, we treated the mice with 25 mg/kg IP paclitaxel or vehicle one day after intravenous challenge.

We found by RV catheterization that the paclitaxel-treated Schistosoma-exposed mice had significantly lower right ventricular systolic pressure (RVSP; Fig. 1b) and less RV hypertrophy (Fig. 1c) compared to vehicle-treated Schistosoma-exposed mice. Further, quantification of the vascular remodeling by immunostaining for α-smooth muscle actin showed significant reduction in the vascular media thickness in paclitaxel treated Schistosoma-exposed mice compared to vehicle-treated Schistosoma-exposed mice (Fig. 1d).

Paclitaxel treatment blocks the type-2 immune response induced by Schistosoma

Inflammation is critical to the pathogenesis of Schistosoma-PH. The immune response in chronic Schistosoma-induced PH is type 2, characterized by the cytokines IL-4 and IL-13. We assessed type-2 immunity by performing ELISA on whole-lung lysates to determine the concentration of IL-4 and IL-13. Paclitaxel-treated Schistosoma-exposed mice had considerably lower IL-4 and IL-13 concentrations (Fig. 2a). The size of the peri-egg granulomas is another indicator of the severity of type-2 inflammation around S. mansoni eggs in the lung. We quantified the estimated granuloma volume and found that paclitaxel-treated Schistosoma-exposed mice had a significantly lower granuloma volume than vehicle-treated Schistosoma-exposed mice (Fig. 2b), also consistent with a decrease in type-2 immunity.

It is also possible that paclitaxel could modulate type-1 immunity, although this is not a characteristic of Schistosoma egg-induced PH. We assayed for the quantity of IFN-γ, the characteristic cytokine of type-1 immunity, and found it to be unchanged by paclitaxel treatment (Fig. 2a).

Paclitaxel treatment decreases CD4 Th2 cells

Th2 CD4+ T cells are major producers of the type-2 immune cytokines IL-4 and IL-13. We analyzed the density and phenotype of CD4+ T cells in Schistosoma IP/IV egg exposed mice using flow cytometry. We found that paclitaxel-treated Schistosoma-exposed mice had fewer CD4+ T cells compared to vehicle-treated Schistosoma-exposed mice (Fig. 2c). We then identified Th-1, Th-2, or Th-17 phenotypes of CD4+ T cells by intracellularly staining for key markers of each type, specifically INF-γ (Th-1), IL-4 (Th-2), and IL-17A or IL-17F (Th-17). There was no change in INF-γ+ CD4+ T cells between paclitaxel and vehicle treated Schistosoma-exposed mice, which is indicative of no type-1 immune activation (Fig. 2d). In contrast, we found the type-2 immune response was blocked by paclitaxel, as there were significantly fewer IL-4+ CD4+ T cells in paclitaxel-treated Schistosoma-exposed mice compared to vehicle treatment. Our assessment of the type-17 immune response had a mixed result, in which IL-17A+ CD4+ T cells were unchanged while IL-17F+ CD4+ T cells were decreased in paclitaxel-treated Schistosoma-exposed mice compared to vehicle treatment. To clarify whether paclitaxel affected the type-17 immune response, we analyzed the whole-lung mRNA concentration of IL-23, which is a marker for the differentiation and activation of Th17 cells. We found no significant difference in IL-23 mRNA concentration in paclitaxel-treated compared to vehicle-treated Schistosoma-exposed mice (Fig. 2e), indicating there was no major change in Th17 immunity.

One possible reason why the RVSPs could be lower in paclitaxel-treated Schistosoma-exposed mice is that they could clear the Schistosoma eggs faster. We tested for this by quantifying the number of eggs left in the lungs at the time of RV catheterization. We found no difference in the residual egg density between paclitaxel-treated and vehicle-treated Schistosoma-exposed mice (Fig. 2f).

Paclitaxel treatment blocks the downstream activation of TGF-β

Activation of TGF-β by the Th-2 immune response is a critical step in developing Schistosoma-PH. We measured the concentration of active TGF-β in whole-lung lysates and found that paclitaxel-treated Schistosoma-exposed mice had significantly lower concentrations of active TGF-β compared to vehicle-treated Schistosoma-exposed mice (Fig. 3a). TGF-β expression is regulated by positive feedback loops. We assessed the total TGF-β concentration by heating the samples to activate all RhoA concentration, a non-canonical signaling target of TGF-β. We found a mild trend towards decreased GTP-RhoA in paclitaxel-treated
Schistosoma-exposed mice compare to vehicle-treated mice ($P = 0.135$; Fig. 3b). This result indicates that there could be a modest suppression of vasoconstriction, in addition to the significant decrease of fixed vascular remodeling, primarily due to Smad-mediated TGF-$\beta$ signaling,$^{11}$ that we identified above as a result of paclitaxel treatment. An alternative target which could be modulated by paclitaxel is the FoxO transcription factors. We quantified the expression of FoxO1 and FoxO3 by RT-PCR and found no changes by paclitaxel versus vehicle treatments (Fig. 3c).

**Paclitaxel treatment did not protect from non-Th-2 mediated (hypoxia-induced) PH**

The decrease in active TGF-$\beta$ in Schistosoma-exposed mice that we observed following paclitaxel treatment could be due to either a direct effect on TGF-$\beta$ such as inhibiting its expression or activation or at the more proximate level of blocking the upstream type-2 immunity. In order to determine whether paclitaxel has a direct effect on the activation of TGF-$\beta$, we tested the effect of paclitaxel in the chronic hypoxia mouse model, which is also TGF-$\beta$ dependent.$^{12,23}$ Chronic hypoxia does not trigger a prototypic type-2 immunity, however, nor is the chronic hypoxia phenotype dependent on type-2 immune signaling.$^{12}$ We exposed C57Bl/6 mice to normobaric hypoxia for two weeks (Fig. 4a) while we treated the mice with 25 mg/kg IP paclitaxel or vehicle weekly. We found by RV catheterization at
the end of the experiment that there was no difference in PH severity between paclitaxel-treated and vehicle-treated hypoxic mice by RVSP (Fig. 4b) or RV hypertrophy (Fig. 4c), indicating that paclitaxel is unlikely to have a direct effect on TGF-β itself.

Discussion

Previous studies have shown that type-2 inflammation and activation of TGF-β are key steps to the pathogenesis of multiple forms of PH, including *Schistosoma*-induced PH.1,8,12 Here, we evaluated the effect of paclitaxel on these two critical steps that lead to development of PH. We found that paclitaxel overall protected against the RVSP, RV hypertrophy, and vascular media thickness induced by *Schistosoma* exposure.

Surprisingly, and in contrast to our hypothesis, we found treatment with paclitaxel blocked the type-2 immune response in *Schistosoma*-exposed mice, despite the previously report that paclitaxel can augment type-2 inflammation in ovalbumin sensitized and challenged mice.14 The evidence we observed that type-2 immunity was suppressed following *Schistosoma* exposure includes lower IL-4 and IL-13 concentrations in whole-lung lysates, fewer CD4+ T cells and Th2-specific CD4+ T cells (which are a key source of the IL-4 and IL-13 cytokines), and smaller peri-egg granulomas. The mechanism by which paclitaxel blocked the type-2 immunity is not clear, but it may have suppressed the recruitment, activation, and/or proliferation of the CD4+ T cells by its anti-proliferative mechanism of action. It is also unclear why the prior report of ovalbumin exposed mice found augmented type-2 immunity with paclitaxel in contrast to our findings; causes for the differences between these two models may be related to the specific antigen, route of administration, or compartment studied: the ovalbumin study used subcutaneous exposure and measured circulating immunoglobulins and splenocyte cytokine expression, as opposed to intravenous *Schistosoma* eggs and lung-specific immunity here. Another possibility is we used a higher dose of paclitaxel than the prior report (about a 500-µg dose for a 20-mg mouse here, versus a 200-µg fixed dose per mouse in the prior study12), potentially accounting for a different impact of Th2 inflammation.

We observed that treatment with paclitaxel lowered the concentration of active TGF-β after *Schistosoma* exposure. This suppression could result from either a direct effect of paclitaxel on TGF-β or its activation (as was reported with skin grafts in a scleroderma mouse model15 and in hepatic stellate cells16), or via an indirect effect through suppression of the proximate type-2 immunity upstream of TGF-β activation. We distinguished between these two possibilities using the chronic hypoxia mouse model, which is TGF-β dependent but type-2 immunity-independent,12,18,24 to determine if paclitaxel has a direct effect on TGF-β activation. We found that chronic hypoxia-exposed mice were not protected from PH by paclitaxel treatment. A possible limitation of these data is that although the paclitaxel was given one day after the start of the hypoxia exposure, this could have been too late to stop an immediate activation of TGF-β in this model. This result suggests that the suppression of TGF-β activation we observed in the *Schistosoma*-PH model was likely due to the suppression of proximate type-2 immunity blocking TGF-β activation, rather than a direct effect of paclitaxel on TGF-β activation itself. Increased TGF-β signaling can also alter the liver fibrosis phenotype in mice infected with *S. mansoni* cercariae, with increased fibrosis observed in BMPR2+/− mice.25

Other mechanisms that could mediate how paclitaxel impacts *Schistosoma*-induced PH is by altering Th1 or Th17 immunity, by decreasing FoxO transcription factors, or by altering the clearance of *Schistosoma* eggs. *Schistosoma* worm antigens (not used here) characteristically trigger type-1 immunity and egg antigens trigger type-2 immunity. We did not identify any change in IFN-γ expression by paclitaxel treatment in this model; indeed, we previously found that IFN-γ is not increased in *Schistosoma* egg challenged mice.3 We also did not observe a change in the density of Th1 CD4+ T cells. Type-17 immunity has been reported to play a key role in the development of chronic inflammatory diseases;21 however, we found no significant change in the protein concentrations of IL-17 or IL-23 with
paclitaxel. We also quantified the mRNA expression of FoxO isoforms 1 and 3, which have been previously implicated in other etiologies of PH, but we did not find any change in either isoform following paclitaxel treatment. Our assessment of FoxO expression could be limited, however, in that FoxO activity can also be regulated at the level of phosphorylation which we did not assess. We also quantified the number of eggs left in the lungs after one week and found that paclitaxel treatment did not appear to block egg clearance in these mice.

In summary, we found that paclitaxel suppresses type-2 immunity, which subsequently downregulates activation of TGF-β and decreases the PH severity following Schistosoma exposure. Paclitaxel may be worthy of further study to prevent or reverse this or other etiologies of PH. However, the use of paclitaxel for patients with schistosomiasis-associated PAH who live in schistosomiasis-endemic areas may not be an optimal therapeutic option, as blocking the type-2 immunity would be potentially harmful in those with ongoing parasite infection or are susceptible to reinfection due to their environmental exposures.

Acknowledgments

Schistosomiasis-infected mice were provided by the NIAID Schistosomiasis Resource Center at the Biomedical Research Institute (Rockville, MD, USA) through NIH-NIAID Contract HHSN272201000051 for distribution through BEI Resources.

Conflict of interest

The author(s) declare that there is no conflict of interest.

Funding

Grant funding was provided by the NIH Grants R01HL133872 (BBG), R01HL133306 (BBG), R01HL135872 (BBG); and American Heart Association Grant 17POST33670045 (RK).

References

1. Butrous G. Saudi guidelines on the diagnosis and treatment of pulmonary hypertension: schistosomiasis and pulmonary arterial hypertension. Ann Thorac Med 2014; 9: S38–41.
2. Graham BB and Kumar R. Schistosomiasis and the pulmonary vasculature (2013 Groover Conference series). Palm Circ 2014; 4: 353–362.
3. Graham BB, Mentink-Kane MM, El-Haddad H, et al. Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling. Am J Pathol 2010; 177: 1549–1561.
4. Chitsulo L, Loverde P and Engels D. Schistosomiasis. Nat Rev Microbiol 2004; 2: 12–13.
5. Papamatheakis DG, Mocumbi AOH, Kim NH, et al. Schistosomiasis-associated pulmonary hypertension. Palm Circ 2014; 4: 596–611.
6. Maizels RM, Balic A, Gomez-Escobar N, et al. Helminth parasites–masters of regulation. Immunol Rev 2004; 201: 89–116.
7. Allen JE and Maizels RM. Diversity and dialogue in immunity to helminths. Nat Rev Immunol 2011; 11: 375–388.
8. Kumar R, Mickael C, Chabon J, et al. The causal role of IL-4 and IL-13 in Schistosoma mansoni pulmonary hypertension. Am J Respir Crit Care Med 2015; 192: 998–1008.
9. Crosby A, Jones FM, Kolosionek E, et al. Praziquantel reverses pulmonary hypertension and vascular remodeling in murine schistosomiasis. Am J Respir Crit Care Med 2011; 184: 467–473.
10. Crosby A, Jones FM, Southwood M, et al. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010; 181: 279–288.
11. Graham BB, Chabon J, Gebreab L, et al. Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni. Circulation 2013; 128: 1354–1364.
12. Kumar R, Mickael C, Kassa B, et al. TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma-and hypoxia-induced pulmonary hypertension. Nat Commun 2017; 8: 15494.
13. Weaver BA. How Taxol/paclitaxel kills cancer cells. Mol Biol Cell 2014; 25: 2677–2681.
14. Yuan L, Wu L, Chen J, et al. Paclitaxel acts as an adjuvant to promote both Th1 and Th2 immune responses induced by ovalbumin in mice. Vaccine 2010; 28: 4402–4410.
15. Liu X, Zhu S, Wang T, et al. Paclitaxel modulates TGFbeta signaling in scleroderma skin grafts in immunodeficient mice. PLoS Med 2005; 2: e354.
16. Zhou J, Zhong D-W, Wang Q-W, et al. Paclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activity. World J Gastroenterol 2010; 16: 3330–3334.
17. Savai R, Al-Tamari HM, Sedding D, et al. Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. Nat Med 2014; 20: 1289–1300.
18. Cahill E, Rowan SC, Sands M, et al. The pathophysiological basis of chronic hypoxic pulmonary hypertension in the mouse: vasoconstrictor and structural mechanisms contribute equally. Exp Physiol 2012; 97: 796–806.
19. Tandrup T, Gundersen HJ and Jensen EB. The optical rotator. J Microsc 1997; 186: 108–120.
20. Abe M, Harpel JG, Metz CN, et al. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994; 216: 276–284.
21. Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflamm Allergy Drug Targets 2012; 11: 159–168.
22. Liu R-M and Desai LP. Reciprocal regulation of TGF-beta and reactive oxygen species: A perverse cycle for fibrosis. Redox Biol 2015; 6: 565–577.
23. Chen Y-F, Feng J-A, Li P, et al. Dominant negative mutation of the TGF-beta receptor blocks hypoxia-induced pulmonary vascular remodeling. J Appl Physiol 2006; 100: 564–571.
24. Ambalavanan N, Nicola T, Hagoood J, et al. Transforming growth factor-beta signaling mediates hypoxia-induced pulmonary arterial remodeling and inhibition of alveolar development in newborn mouse lung. Am J Physiol Lung Cell Mol Physiol 2008; 295: L86–95.
25. Crosby A, Soon E, Jones FM, et al. Hepatic shunting of eggs and pulmonary vascular remodeling in Bmpr2(+/−) mice with schistosomiasis. *Am J Respir Crit Care Med* 2015; 192: 1355–1365.

26. Deng C, Zhong Z, Wu D, et al. Role of FoxO1 and apoptosis in pulmonary vascular remodeling in a rat model of chronic thromboembolic pulmonary hypertension. *Sci Rep* 2017; 7: 2270.

27. Wang D, Zhang H, Li M, et al. MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts. *Circ Res* 2014; 114: 67–78.